Prescient Therapeutics Ltd (FRA:UDD)
€ 0.11 0 (-5.17%) Market Cap: 82.40 Mil Enterprise Value: 73.69 Mil PE Ratio: 0 PB Ratio: 1.86 GF Score: 22/100

Prescient Therapeutics Ltd Meeting on the Mesa Transcript

Oct 21, 2022 / NTS GMT
Steven Yatomi;Clarke
Prescient Therapeutics Limited - CEO, MD

Hi, everyone. Thanks for coming, and thanks for the opportunity to present protein therapeutics. We are an Australia US company listed in Australia with private subsidiaries, relatively new to the cell therapy field about three years now, a provocative images, we don't apologize for our ambitions. But I think also to highlight that I'm having the right technology is not enough you need to have the right technology at the right time. And we think we find ourselves in a nice sweet spot.

Looking to solve the problems that you're all very familiar with this learned audience in cell therapy with two platforms, one, OmniCAR, which I'll introduce you to, and the other one, recently announced cell therapy enhancement platform called CellPryme with they overlap, they do so synergistically.

So OmniCAR is a universal immune receptor platform that we've licensed from UPenn, a deliberate collaboration between the cell biologists and protein engineers to come up with a modular system. Some of you might be familiar with some

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot